Innate Pharma SA
PAR:IPH

Watchlist Manager
Innate Pharma SA Logo
Innate Pharma SA
PAR:IPH
Watchlist
Price: 1.616 EUR 0.87% Market Closed
Market Cap: 149m EUR

Innate Pharma SA
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Innate Pharma SA
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Innate Pharma SA
PAR:IPH
Revenue
€6m
CAGR 3-Years
-49%
CAGR 5-Years
-34%
CAGR 10-Years
18%
Valneva SE
PAR:VLA
Revenue
€291.4m
CAGR 3-Years
-10%
CAGR 5-Years
19%
CAGR 10-Years
17%
Nanobiotix SA
PAR:NANO
Revenue
-€14m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Revenue
€13.6m
CAGR 3-Years
49%
CAGR 5-Years
18%
CAGR 10-Years
N/A
DBV Technologies SA
PAR:DBV
Revenue
$3.8m
CAGR 3-Years
-27%
CAGR 5-Years
-30%
CAGR 10-Years
-3%
Abivax SA
PAR:ABVX
Revenue
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Innate Pharma SA
Glance View

Market Cap
148.7m EUR
Industry
Biotechnology

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. The company is headquartered in Marseille, Paca and currently employs 215 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The firm works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.

IPH Intrinsic Value
1.797 EUR
Undervaluation 10%
Intrinsic Value
Price

See Also

What is Innate Pharma SA's Revenue?
Revenue
6m EUR

Based on the financial report for Jun 30, 2025, Innate Pharma SA's Revenue amounts to 6m EUR.

What is Innate Pharma SA's Revenue growth rate?
Revenue CAGR 10Y
18%

Over the last year, the Revenue growth was -76%. The average annual Revenue growth rates for Innate Pharma SA have been -49% over the past three years , -34% over the past five years , and 18% over the past ten years .

Back to Top